Midatech Pharma Gets Verbal Approval For MTD201 Continued Development
Source: Pixabay

Midatech Pharma Gets Verbal Approval For MTD201 Continued Development

Midatech Pharma just received verbal confirmation from Polish regulators to conduct the first European in-human study for a treatment that could potential aid those with carcinoid cancer and acromegaly, reported…

Continue Reading Midatech Pharma Gets Verbal Approval For MTD201 Continued Development
PharmaCare in British Columbia Refuses to Cover Medication for Juvenile Idiopathic Arthritis
source: pixabay.com

PharmaCare in British Columbia Refuses to Cover Medication for Juvenile Idiopathic Arthritis

According to a story from CBC News, Jillian Lanthier's son Landen Alexa was diagnosed with a severe and rare form of juvenile idiopathic arthritis at six years old. Although he…

Continue Reading PharmaCare in British Columbia Refuses to Cover Medication for Juvenile Idiopathic Arthritis
This Tournament is Raising Money for Colitis and Crohn’s Disease Research
source: pixabay.com

This Tournament is Raising Money for Colitis and Crohn’s Disease Research

According to a story from Syosset Jericho Tribune, the charity basketball fundraiser called Hoops for Harrison is back again this year. The tournament was named after Harrison Gillman, who now…

Continue Reading This Tournament is Raising Money for Colitis and Crohn’s Disease Research
A Conditional Application for a New Vasculitis Treatment Was Just Accepted By The EMA
source: pixabay.com

A Conditional Application for a New Vasculitis Treatment Was Just Accepted By The EMA

According to a story from ANCA Vasculitis News, The European Medicines Agency just approved the pharmaceutical company ChemoCentryx's application for the marketing of avacopan as a potential treatment for anti-neutrophil…

Continue Reading A Conditional Application for a New Vasculitis Treatment Was Just Accepted By The EMA
Report: Pharma Can Resume Testing Drug Efficacy for Neurological and Respiratory Conditions
Source: Pixabay

Report: Pharma Can Resume Testing Drug Efficacy for Neurological and Respiratory Conditions

RespireRx Pharmaceuticals announced last month it was cleared to resume its ampakine CX717 clinical trials to evaluate the drug’s efficacy in several central nervous system and respiratory disorders, including Pompe…

Continue Reading Report: Pharma Can Resume Testing Drug Efficacy for Neurological and Respiratory Conditions
These Researchers Have Discovered The Truth About Idiopathic Pulmonary Fibrosis
source: pixabay.com

These Researchers Have Discovered The Truth About Idiopathic Pulmonary Fibrosis

New research is helping experts understand the underlying causes of idiopathic pulmonary fibrosis on the molecular scale. When solving any problem, disease included, it is best to start by understanding…

Continue Reading These Researchers Have Discovered The Truth About Idiopathic Pulmonary Fibrosis
CureVac Partners with Arcturus Therapeutics to Target Ornithine Transcarbamylase Deficiency
Source: Pixabay

CureVac Partners with Arcturus Therapeutics to Target Ornithine Transcarbamylase Deficiency

Another successful partnership in the rare disease community has come to fruition, reports The Pharma Letter. Just this past week, CureVac and Arcturus Therapeutics will become a powerhouse together with…

Continue Reading CureVac Partners with Arcturus Therapeutics to Target Ornithine Transcarbamylase Deficiency